Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG2737 in autosomal dominant polycystic kidney disease
2019-003521-21Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing GLPG2737 with Placebo → GLPG2737 (2 arms). Primary endpoint: Mean percent change from baseline of height-adjusted total kidney volume (htTKV). Started Oct 2019; status: terminated.
02
Drugs
GLPG2737
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2019-003521-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003521-21.